Pacira Pharmaceuticals Inc (PCRX)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 61,701 | 13,302 | 56,404 | 20,089 | -10,748 |
| Revenue | US$ in thousands | 636,266 | 626,907 | 541,533 | 429,647 | 421,026 |
| Pretax margin | 9.70% | 2.12% | 10.42% | 4.68% | -2.55% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $61,701K ÷ $636,266K
= 9.70%
Pacira BioSciences Inc's pretax margin has shown variability over the past five years. The trend indicates that the company's ability to generate profits before taxes has fluctuated significantly. In 2023, the pretax margin improved to 9.14%, showing a positive performance compared to the previous year. However, in 2022, the pretax margin was relatively lower at 1.99%, which may indicate operational challenges or increased expenses impacting profitability.
The highest pretax margin of 10.42% was achieved in 2021, reflecting a period of strong profitability for the company. The pretax margin of 4.68% in 2020 also indicates a moderate level of profitability, although lower than the peak year. Notably, in 2019, Pacira BioSciences Inc experienced a negative pretax margin of -2.55%, suggesting a period of losses or financial difficulties.
Overall, Pacira BioSciences Inc's pretax margin has exhibited fluctuations, with both highs and lows in profitability performance over the past five years. It is essential for the company to analyze the factors contributing to these variations to maintain and improve its financial health and sustainable profitability in the future.
Peer comparison
Dec 31, 2023